Monoferric (Ferric Derisomaltose) Patent Expiration, LOE Window & CMS Spending
Monoferric (Ferric Derisomaltose) by Pharmacosmos As: FDA Orange Book core substance LOE 2029-08-14 (last listed 2036-06-22), 0 AB generics, $16.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pharmacosmos As |
| FDA Application & Pathway | N208171 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2029-08-14 |
| Last Listed Patent or Exclusivity Date | 2036-06-22 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $16.2M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $16.2M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 39.7% 2-yr change) |